Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers developed and optimized squarticles containing rosuvastatin calcium and found that they promoted hair regrowth in rats within 10 days, showing superior results compared to the standard minoxidil treatment.

In this animal study, atorvastatin co-administered with trastuzumab reversed trastuzumab-induced cognitive impairment (chemo-brain) and improved its anti-cancer efficacy without causing hair loss.

This article describes cutaneous reactions including keratosis pilaris-like eruptions in a patient on nilotinib for chronic myelogenous leukemia, emphasizing the importance of accurately classifying such eruptions.

This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.

This review highlights that while sonidegib and vismodegib offer promising treatment options for advanced basal cell carcinoma, their use is often limited by treatment-emergent adverse events, which can be managed through protocol modifications and supportive interventions.

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

In this study, pemetrexed combined with cisplatin for advanced NSCLC treatment had similar efficacy to gemcitabine but resulted in significantly fewer adverse reactions.

This study identified neprilysin as a potential target of the pharmacological agent arteannuin, which may guide future research into its clinical applications, although experimental verification is needed.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

The study reported that vismodegib showed significant effectiveness in treating basal cell carcinoma, particularly in patients with Gorlin-Goltz syndrome or locally advanced BCC, but also highlighted substantial side effects, requiring careful management to prevent treatment resistance and maintain remission.

This study in ND-GFP transgenic mice found doxorubicin inhibited both tumor angiogenesis and growth, visualized through dual-color fluorescence imaging of nascent blood vessels and melanoma cell lines.

This meta-analysis suggests that combining Kang-ai injection with platinum-based chemotherapy may improve tumor response, performance status, immune functions, and reduce adverse reactions in patients with advanced non-small cell lung cancer.

In this literature review, researchers compiled evidence on repurposed synthetic radioprotective agents, including metformin and simvastatin, that have demonstrated potential in mitigating the side effects of radiotherapy in cancer treatment.

This study reported that targeted anticancer therapies are associated with an increased risk of alopecia compared to placebo, although the risk was lower compared to chemotherapy.

This article discusses the importance of recognizing adverse drug reactions, methods of prevention, and encourages reporting them to the FDA's MedWatch program; it reports no new results.

This study aims to assess the effectiveness of the YH0618 granule in reducing chemotherapy-induced hair loss in breast cancer patients, without disrupting anti-tumor effects, by conducting a randomized, double-blind trial. Results are not reported in the abstract.

Atorvastatin may cause hair loss in some people.

The committee unanimously voted against recommending approval of the injectable cisplatin/epinephrine gel IntraDose for certain head and neck cancer patients, citing insufficient clinical benefit and concerns about toxicity in this study.

In this study, deleting the -catenin gene in vitamin D receptor-null mice did not prevent tumor development, suggesting -catenin's predicted protective role was not observed.

In this study, researchers examined a patient with ZMYM2::FGFR1 fusion-positive leukemia, finding that Pemigatinib showed efficacy, while Ponatinib resistance was linked to a specific FGFR1 mutation. Other FGFR inhibitors demonstrated high effectiveness in ex vivo assays.

The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.

This study found that Golvatinib, Gliquidone, and Dihydroergotamine may inhibit the binding of SARS-CoV-2's Nsp1 protein to the host ribosomal subunit, suggesting potential as treatments against COVID-19 variants.

This study observed that 71% of chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors experienced adverse cutaneous reactions, which were generally less severe than those caused by imatinib.

This paper provides a comprehensive list of drugs including Ethamolin, Placidyl, Trecator-SC, Zarontin, Peganone, Didronel, and Lodine, detailing their indications, potential interactions, and reported adverse skin reactions, but it presents no new research findings.

In this study, researchers will conduct a randomized, double-blind, multi-center clinical trial to assess the effectiveness of YH0618 granule in preventing chemotherapy-induced hair loss among breast cancer patients, aiming to understand its mechanism related to kidney deficiency in Chinese Medicine. Results are not yet reported.

This abstract discusses the importance of controlling visible abdominal tumors in women with ovarian cancer to improve survival, and notes that nonvisible microscopic tumors are then targeted with chemotherapy; it reports no new results.

This study found that vitamin A treatment in rats reduced hyperplastic-dysplastic changes and sebaceous gland hypertrophy associated with 3,4-benzpyrene-induced tumors.

This review summarizes evidence and adverse event management recommendations for Sacituzumab Govitecan in metastatic triple-negative breast cancer and hormone receptor-positive breast cancer, emphasizing favorable survival data from clinical trials.

In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.

This study discusses a hypothesis for repurposing non-cancer drugs and combining micronutrients to target cancer and cancer stem cells with fewer side effects, suggesting a potential new approach for more effective cancer therapy.